Multisystem Inflammatory Syndrome in U.S. Children and Adolescent

This study conducted active surveillance for multisystem inflammatory syndrome in children (MIS-C) across 26 U.S. states between March and May 2020. Among 186 hospitalized patients under age 21, most had no preexisting conditions and presented with fever and multi-organ involvement—most commonly gastrointestinal, cardiovascular, and respiratory systems. Approximately 80% required intensive care, and 2% died. Cardiovascular dysfunction, including shock requiring vasoactive support and coronary aneurysms, was prominent. SARS-CoV-2 infection was confirmed in most patients, with a median 25-day interval between COVID-19 symptom onset and MIS-C. The majority received immunomodulatory treatment, including IVIG and corticosteroids. The findings highlight the severity and hyperinflammatory nature of MIS-C following COVID-19 infection.

This study conducted active surveillance for multisystem inflammatory syndrome in children (MIS-C) across 26 U.S. states between March and May 2020. Among 186 hospitalized patients under age 21, most had no preexisting conditions and presented with fever and multi-organ involvement—most commonly gastrointestinal, cardiovascular, and respiratory systems. Approximately 80% required intensive care, and 2% died. Cardiovascular dysfunction, including shock requiring vasoactive support and coronary aneurysms, was prominent. SARS-CoV-2 infection was confirmed in most patients, with a median 25-day interval between COVID-19 symptom onset and MIS-C. The majority received immunomodulatory treatment, including IVIG and corticosteroids. The findings highlight the severity and hyperinflammatory nature of MIS-C following COVID-19 infection.